Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — LD Micro Main Event 2015
19 slides from Bionik Laboratories's conference presentation, Dec 3, 2015
Slide 1: LD Micro Main Event, December 3, 2015
www.bioniklabs.com OTCQX:BNKL LD Micro Main Event December 3, 2015 Peter Bloch, Chief Executive Officer
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward - looking statements relating to future events or the future financial performance and operations of Bionik . Forward - looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business op
Slide 3: Bionik Overview
Bionik Overview • Pioneering medical device and robotics company with a focus in developing transformational technologies and solutions for individuals with neurological disorders • Core product ARKE™: Lower body exoskeleton initially targeting rehabilitation market • Potential Canadian and CE filin
Slide 4: ARKE
ARKE A robotic lower body exoskeleton designed to allow paraplegics as well as other wheelchair users, the ability to rehabilitate through walking TM
Slide 5: ARKE: Product Details
ARKE: Product Details • Sensors throughout the device sense body movement and trigger motion • Constructed with carbon fiber, aluminum and steel • Fully customizable to fit patients of all heights and weights • Connects to Bionik’s cloud software where data is analyzed and displayed back to the phys
Slide 6: Healthcare Cost – SCI & Stroke
Healthcare Cost – SCI & Stroke Spinal Cord Injuries [1] • Length of initial hospitalization following injury in acute care units: 11 days • Average stay in - patient rehabilitation unit: 36 days • Average Lifetime Costs ( 3 ) : Stroke • In the US, h eart attack and stroke costs are estimated at over
Slide 7: Sizing the Market
Sizing the Market • There are approximately 276,000 people living with SCI in the USA, with an estimated annual 12,500 new cases. (1) Across the G20 this translates to an estimated 4,000,000 existing SCI and annual new 180,000 cases. • Of the global, annual, 16,000,000 stroke cases, 5,000,000 people
Slide 8: Competitive Landscape
Competitive Landscape Company & Device Selling Price Status Tech Points REWALK (RWLK: NASDAQ) - Rewalk Personal 6.0 System $ 69,500 in USA € 52,500 in EU - CE Marks and FDA cleared for personal and rehabilitation use - FDA De Novo created PHL category; a new classification paradigm for powered exosk
Slide 9: Business Model
Business Model 9 In - Patient Rehab • Lease/Rental model • Monthly fee to the hospital/clinic for use of the product Out - Patient Rehab • Revenue share or Lease/Rental model • Percentage of the per session therapy to Bionik Home Use • Rental or direct product sale • ARKE revenue can be generated by
Slide 10: Reimbursement
Reimbursement • No universal coverage; however successful reimbursement on a case - by - case has been achieved • Etiology of injury impacts financing plan – e.g. vehicle accidents (automobile liability and Personal Injury Protection); workplace (workman’s compensation); fall at home (home insurance
Slide 11: ARKE: Path to Commercialization
ARKE: Path to Commercialization 11 Market Canada European Union United States Regulating Authority Health Canada Medical Device Regulations (MDR) Notified Body Medical Device Directive (MDD) Food & Drug Administration 21 CFR Classification Class I Class II a Class II w/ special controls License Aven
Slide 12: Pipeline Expansion Opportunities
Pipeline Expansion Opportunities Pipeline Products Discovery Prototyping Optimization Pre - clinical Clinical Approval ARKE TM PARAPLEGIC REHABILITATION Pipeline Expansion Opportunities Research Products Discovery Prototyping Optimization Pre - clinical Clinical Approval BNKL - 002 ARKE TM STROKE BN
Slide 13: Robust Intellectual Property
Robust Intellectual Property Area Of IP Status Filing Year Algorithms & Control Systems Filed US & International 2012 Sensory Technology Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics US Prov
Slide 14: Growth Strategy Supports Further Pipeline Expansion
Growth Strategy Supports Further Pipeline Expansion • Leveraging internal expertise and broad network to develop new synergistic technologies • Team dedicated to expanding product pipeline through strategic partnering and acquisitions with products and enabling software 14 Expanded and Focused Devel
Slide 15: Management Team
Management Team • Peter Bloch, CPA, CA – Chief Executive Officer • Over 25 years of executive management experience with proven track record of building public and private technology companies. Former CFO and joint Interim CEO of Sanofi Canada, CFO of Intellivax , Gennum TSX:GNM (n/k/a Semtech NASDA
Slide 16: Board and Advisors Strengthens Capabilities
Board and Advisors Strengthens Capabilities Advisors • Gary Henley • Significant medtech experience • Former CEO of United Orthopedic Group, Wright Medical Technology, CeCorp and Electronic Systems • Board Director of numerous companies • Dr. Isador Lieberman, MD MBA FRCSC • Medical Director, Clinic
Slide 17: Financial Snapshot
Financial Snapshot - OTCQX: BNKL Stock Ticker Symbol OTCQX: BNKL Market Capitalization as of November 30 , 2015 $87.6 M Shares Outstanding 72.4 M** Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.64 M R ecent financings: February - July , 2015 $13.1 M Cash as of Sept
Slide 18: Near-term Milestones
Near - term Milestones 201 5 H2 201 6 H1 201 6 H2 201 7 H1 Pre - clinical v erification testing gen 2 - ARKE Clinical evaluations - ARKE First clinical data readout - ARKE Targeted Health Canada MDEL & CE Mark Filings - ARKE Expected Health Canada license & CE Marks Registration - ARKE Formal Clinic
Slide 19: www.bioniklabs.com
www.bioniklabs.com OTCQX:BNKL LD Micro Main Event December 3, 2015 Peter Bloch, Chief Executive Officer